TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03655119

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent toolkit
Description: The parent tookit is a resource that reinforces evidence-based practices for crisis management such as safety planning and means restriction and encourages parents to increase their support, supervision, and monitoring of their at risk youth.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent toolkit
Description: The parent tookit is a resource that reinforces evidence-based practices for crisis management such as safety planning and means restriction and encourages parents to increase their support, supervision, and monitoring of their at risk youth.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Care
Description: PES clinical staff will receive training on the best practices in brief crisis-focused interventions in emergency settings with parents and youth.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Care
Description: PES clinical staff will receive training on the best practices in brief crisis-focused interventions in emergency settings with parents and youth.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caring Follow-Up Messages
Description: Parents will receive caring contacts via phone, text, or email to provide support, additional education, and problem solving assistance in the days and weeks post-discharge.
Study: NCT02102919

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SR-WBV
Description: Participants will undergo a training program set over eight weeks, three times a week with 3 to 6 Hz, Noise 4.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Games (VG)
Description: Participants will undergo a training program set from week 5 to 8, three times a week over 20 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: SR-WBV
Description: Participants will undergo a training program set over eight weeks three times a week with 1 Hz, Noise 1.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Aktiv Tramp (Swiss Frei AG, Switzerland)
Description: Participants will undergo a training program set from the 5 to 8 week, three times a week with 1Hz.
Study: NCT01008150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Study: NCT02101073

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0061
Description: single dose, intravenous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0061
Description: single dose, intravenous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0061
Description: single dose, subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0061
Description: single dose, subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0061
Description: single dose, subcutaneous
Study: NCT02418624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin, olaparib
Description: 2 cycles of carboplatin and olaparib combination therapy followed by olaparib monotherapy.
Study: NCT01006967

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ActiveStep Treadmill
Description: The ActiveStep treadmill is a device that trains patients to effectively react to simulated slips and trips while the patient is safely held in a harness.
Study: NCT03435107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Study treatment consists of durvalumab 1500 mg Q4W for patients \> 30 kg, and will be repeated every 4 weeks. For patients ≤ 30 kg, weight based dosing of 20 mg/kg durvalumab Q4W will be used.~Response evaluation will be performed every 8 weeks (± 1-week window period). Treatment will be continued until disease progression, unacceptable adverse events or the patient's refusal.~Treatment through progression is at the investigator's discretion, and the investigator should ensure that patients do not have any significant, unacceptable, or irreversible toxicity that indicate that continuing treatment will not further benefit the patient. The Investigator should ensure that patients still meet all of the inclusion criteria and none of the exclusion criteria for this study.
Study: NCT04482803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbon nanoparticles suspension injection will be injected into or around the cortex of the clinically assessed positive lymph nodes
Description: Before NST, one of the clinically assesed positive lymph nodes will be subjected to ultrasound-guided CNB or FNA, and a locating clip (Ultraclip, BARD) will be placed. Meanwhile, a small amount of Kanarine (carbon nanoparticles suspension injection, 0.5ml:25mg, H20073246) will be injected into or around the cortex of the locating lymph node and other clinically assessed positive lymph nodes. Preoperative FNA will be performed again for locating clip labelled node.
Study: NCT03492294

Intervention type: DIAGNOSTIC_TEST
Intervention: functional magnetic resonance imaging
Description: Patients with disorders of consciousness were assessed by functional magnetic resonance imaging while they were exposed under the condition of music.
Study: NCT03087149

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: monitored vit D supplementation
Description: The vit D supplementation dose start from dose 500IU from 7th day of age and is modified based on vit D measurement at 4 week of age for infants born \<30 GA, at 8 week of age for infants born \<26 GA at 35+/-2 weeks PMA(postmenstrual age), +/-at 40+/-2 weeks PMA according to the protocol.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: standard vit D supplementation
Description: The vitamin D supplementation dose is 500IU from 7th day of age.
Study: NCT02364895

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Males control group: Deferred letter
Description: This letter will be sent 6 months after index (mailing) date

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Males Group 1: Current CCC invitation letter
Description: This letter is currently used by the program in 50-54 year olds

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Males Group 2: New letter with neutral gender content
Description: Unisex letter
Study: NCT03908138

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RDD
Description: Lenalidomide: 25mg, po, d1-21， Pegylated Liposomal Doxorubicin: 30-40mg/m2，ivgtt, d1 Dexamethasone: 20-40mg, po, d1，d8，d15，d22
Study: NCT02364895

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Males Group 3: New letter with male-specific content
Description: New letter tailored for men

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Females control group: Deferred letter
Description: This letter will be sent 6 months after index (mailing) date
Study: NCT01008150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Study: NCT02364895

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Females Group 1: Current CCC invitation letter
Description: This letter is currently used by the program in 50-54 year olds
Study: NCT01008150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Study: NCT03908138

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VDD
Description: Bortezomib:1.3mg/m2，ih，d1，d4，d8，d11 Pegylated Liposomal Doxorubicin: 30-40mg/m2，ivgtt, d1 Dexamethasone: 20 mg, ivgtt, d1, 2, 4, 5, 8, 9, 11,12
Study: NCT01598727

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluobeam(TM) Imaging System (Fluoptics)
Description: Use of 'Fluobeam(TM)' (Fluoptics) as an intraoperative real time fluorescence detection system during surgery
Study: NCT01008150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Study: NCT02364895

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Females Group 2: New letter with neutral gender content
Description: Unisex letter
Study: NCT01008150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study: NCT00251355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine, IV bolus administered weekly (weeks 1-6) at least 4 hours before that day's radiation therapy.
Study: NCT01736202

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: fat orally
Description: Oral ingestion of palm oil or canola oil or water at timepoint zero

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: fat orally
Description: Oral ingestion of palm oil or canola oil or water at timepoint zero
Study: NCT00251355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-FU via continuous IV infusion.
Study: NCT01736202

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: fat orally
Description: Oral ingestion of palm oil or canola oil or water at timepoint zero
Study: NCT00251355

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: External Beam Radiotherapy (weeks 1-6), Monday through Friday.
Study: NCT02415257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin
Description: Intratympanic installation of gentamicin 2-4 times depending on the efficacy of vestibular deafferentation
Study: NCT04857970

Intervention type: OTHER
Intervention: Electronic HRQoL questionnaires with feedback to physicians
Description: Use of the CHES software for HRQoL collection and graphical display of the patients' HRQoL scores to physicians

Intervention type: OTHER
Intervention: Paper-pencil HRQoL questionnaires w.o. feedback to physicians
Description: Use of paper-pencil HRQoL questionnaires, the results of which are not presented to physicians
Study: NCT02148107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 691751
Description: BI 691751 Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 691751
Description: BI 691751 Dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 691751
Description: BI 691751 Dose 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 691751
Description: BI 691751 Dose 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 691751
Description: BI 691751 Dose 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 691751
Description: BI 691751 Dose 6

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03751644

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: Patients with systemic autoimmune myopathies will receive peripheral electrical stimulation in thigh muscles
Study: NCT02025166

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Pain treatment with aniline analgesics (paracetamol) at the time of the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Pain treatment with aniline analgesics (paracetamol) at the time of the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lornoxicam
Description: Pain treatment with NSAID (lornoxicam) at the time of the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lornoxicam
Description: Pain treatment with NSAID (lornoxicam) at the time of the procedure
Study: NCT00072631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva (Trademark) (erlotinib HCl, OSI-774)
Description: Intrapatient dose escalation of oral single agent daily erlotinib until intolerable rash
Study: NCT03719820

Intervention type: DRUG
Intervention: aggressive medical management
Description: Aspirin (100 mg daily) and Clopidogrel (75 mg daily) for 3 months and Rosuvastatin (20mg daily) for at least 6 months as well as traditional risk factors management
Study: NCT03845543

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luminor-14 Paclitaxel eluting balloon
Description: Patients will be treated with the Luminor-14 paclitaxel eluting balloon
Study: NCT04214873

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PiQo4 Laser System
Description: PiQo4 Laser System for treatment of POH
Study: NCT00571610

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant
Description: Percutaneous access from right or left subclavian vein, diagnostic assessment, then placement of the PTMA implant in the coronary sinus, great cardiac vein.
Study: NCT03381794

Intervention type: PROCEDURE
Intervention: Corneal transplantation
Description: PKP: Penetrating Keratoplasty DALK: Deep Anterior Lamellar Keratoplasty DMEK: Descemet Membrane Endothelial Keratoplasty DSAEK: Descemet's Stripping Automated Endothelial Keratoplasty
Study: NCT00845923

Intervention type: DRUG
Group type: OTHER
Intervention: Civamide Patch
Description: Patch containing Civamide (zucapsaicin) 0.015%, containing 0.210 mg Civamide per patch, applied once a day for four weeks.
Study: NCT03997968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT-0851
Description: Part A and B: Daily oral doses of CYT-0851 for 28 day cycles
Study: NCT03768661

Intervention type: PROCEDURE
Intervention: Single-incision Laparoscopic cholecystectomy
Description: laparoscopic cholecystectomy performed through a single device located at a unique umbilical incision

Intervention type: PROCEDURE
Intervention: Laparoscopic Cholecystectomy
Description: laparoscopic cholecystectomy performed using three-trocars standard technique
Study: NCT02985697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The intervention being tested is intranasal dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The intervention being tested is intranasal dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The intervention being tested is intranasal dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam Hydrochloride
Description: Oral midazolam is being used as the Active Comparator. It will also be used in conjunction with IN dexmedetomidine in some experimental groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam Hydrochloride
Description: Oral midazolam is being used as the Active Comparator. It will also be used in conjunction with IN dexmedetomidine in some experimental groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam Hydrochloride
Description: Oral midazolam is being used as the Active Comparator. It will also be used in conjunction with IN dexmedetomidine in some experimental groups.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous Oxide
Description: Nitrous oxide to be administered in conjunction with other interventions, per study design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: Nitrous oxide to be administered in conjunction with other interventions, per study design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: Nitrous oxide to be administered in conjunction with other interventions, per study design.
Study: NCT04902742

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopy-guided ganglion impar block
Description: Fluoroscopy guidance is used for correct visualization of injection site, and so obtained more successful results. Patients are placed in the prone position. Injection site is cleaned thrice with povidone iodine %10 solution and covered with sterile drapes. Being most commonly used technic, transsacrococcygeal technique, a 22-gauge, 1.5-inch spinal needle is advanced through the sacrococcygeal disk and positioned carefully anterior to the sacrococcygeal junction. Injection of contrast results in a classical comma sign. A mixture of steroid and local anesthetic is given.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopy-guided caudal epidural steroid injection
Description: Fluoroscopy guidance is used for correct visualization of injection site, and so obtained more successful results. Patients are placed in the prone position. Injection site is cleaned thrice with povidone iodine %10 solution and covered with sterile drapes. An 18-gauge epidural needle (Tuohy) is advanced at an angle of 45° to the skin until a 'give-way' sensation is felt and position of the needle is confirmed by lateral and anteroposterior fluoroscopic images. Then 5 ml of iohexol solution is injected through it to confirm the position. A properly placed needle would produce a classical 'inverted fern tree' appearance in anteroposterior view after dye injection or a 'filling defect'. The needle is introduced up to S3 level for proper spread of the drug. A mixture of steroid and local anesthetics is given.
Study: NCT03746275

Intervention type: DRUG
Intervention: Rivaroxaban (BAY59-7939, Xarelto)
Description: 2.5 mg twice daily

Intervention type: DRUG
Intervention: Acetylsalicylic acid
Description: 75 - 100 mg once daily according to local label
Study: NCT03863717

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm Endurance Exercise Training
Description: Pulmonary Rehabilitation Program including Upper Limb Endurance Exercise Training with arm cycle ergometer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Pulmonary Rehabilitation Program without Upper Limb Endurance Exercise Training
Study: NCT03968887

Intervention type: OTHER
Intervention: plasma oxidized low-density lipoprotein levels
Description: Detection of plasma oxidized low-density lipoprotein levels

Intervention type: OTHER
Intervention: plasma oxidized low-density lipoprotein levels
Description: Detection of plasma oxidized low-density lipoprotein levels
Study: NCT04568889

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Messaging
Description: Individuals will see no messaging in the baseline survey.
Study: NCT00514423

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducation by professonals

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducation by peer-moderators

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video-education

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Noneducational video group (control group)
Study: NCT01038193

Intervention type: OTHER
Intervention: Cognitive assessment
Description: Cognitive and functional assessments at 2-4 weeks, 3 months and 12 months.
Study: NCT02193581

Intervention type: DEVICE
Intervention: MDS
Description: Patients with a suspicious lesion, referred for a biopsy is tested using MDS.
Study: NCT03577873

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: gallbladder preserved
Description: Gallbladders will be remained after clearance of bile duct stones with ERCP and conventional therapy, such as fluid replacement and prophylactic anti infection, will be accepted.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cholecystectomy
Description: Cholecystectomy will be done right now after clearance of bile duct stones with ERCP, and then conventional therapy will be accepted.
Study: NCT00805948

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Talent Thoracic Stent Graft System
Description: endovascular repair of descending thoracic aortic aneurysms using the Talent Thoracic Stent Graft System.
Study: NCT03296579

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiPAP
Description: The patient's breathing is assisted by cycling between high and low pressures at a pre-set rate.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: The patient breathes against a constant pressure delivered by face mask.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipratropium
Description: Nebulized q6h
Study: NCT01006967

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Standard program of physical therapy for gait and balance
Study: NCT03111667

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teen Marijuana Check Up
Description: Two session Motivational Enhancement Therapy intervention. The first MET session relies on the use of motivational interviewing skills to hear the student's history and current concerns with marijuana. The second session involves the provision of a personalized feedback report based on the student's baseline assessment that reviews normative feedback on marijuana use, consequences experienced, money spent on marijuana, other drug and alcohol use, social supports for quitting and life goals.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: Referral to community resources

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gold Standard Coaching
Description: Weekly coaching and feedback about adherence to Motivational Interviewing Skills and intervention delivery in a group setting.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: As Needed Coaching
Description: As needed coaching and feedback about adherence to Motivational Interviewing Skills and intervention delivery in an individual setting.
Study: NCT01072799

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two doses (Day 1 and Day 22); 0.5mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H1N1 2009 Influenza VLP Vaccine
Description: Two doses (Day 1 \& Day 22); 0.5mL
Study: NCT03296579

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: 50mg/kg IV, 4 doses q6h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminophylline
Description: 6mg/kg IV (if no progress)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard steroid dose, hourly salbutamol, oxygen as needed
Description: Standard common therapies for all three arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard steroid dose, hourly salbutamol, oxygen as needed
Description: Standard common therapies for all three arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard steroid dose, hourly salbutamol, oxygen as needed
Description: Standard common therapies for all three arms.
Study: NCT04320264

Intervention type: PROCEDURE
Intervention: Weight loss surgery
Description: Severely obese women (BMI \>40) undergo sleeve gastrectomy
Study: NCT02552550

Intervention type: PROCEDURE
Intervention: Ability to swallow, speak and quality of life
Description: This study will not change the patient's treatment. This will just be an evaluation, before any treatment, his ability to swallow, speak, then his quality of life, as in normal practice, after 3, 6 and 12 months after treatment.